نتایج جستجو برای: روغن سویای اپوکسی دارشده eso
تعداد نتایج: 12646 فیلتر نتایج به سال:
چکیده زمینه و هدف: تحقیقات بسیاری در زمینه ی اثرات ضد درد حاصل از تجویز خوراکی یا تزریقی انواع روغن ها انجام شده است. یکی از این مطالعات نشان داده که تجویز خوراکی روغن سویا بر درد ناشی از سرطان استخوان اثر مفیدی داشته است. با توجه به گزارشات پیشین درمورد تأثیر بی دردی روغن سویا در تجویز محیطی و از آن جایی که در تحقیقات مختلف این روغن به عنوان حلال و یا در تهیه ی امولسیون برای مطالعه ی اثر ضددرد...
مقدمه: امروزه استفاده از گیاهان دارویی و ترکیبات موثره‌ی آن‌ها به عنوان منابع طبیعی که دارای خاصیت آنتی‌اکسیدانی هستند، مورد توجه محققین قرار گرفته است. آنتی‌اکسیدان‌ها ترکیباتی هستند که به طور موثر و به طرق مختلف از واکنش رادیکال‌های آزاد دارای اکسیژن و نیتروژن فعال با بیومولکول‌ها (نظیر پروتئین، آمینو‌اسید، لیپید و DNA) جلوگیری کرده و منجر به کاهش آسیب و یا مرگ سلولی، بیماری‌های قلبی عروقی ...
PURPOSE NY-ESO-1 cancer testis (CT) antigen is an attractive candidate for immunotherapy as a result of its high immunogenicity. The aim of this study was to explore the potential for NY-ESO-1 antigen directed immunotherapy in triple negative breast cancer (TNBC) by determining the frequency of expression by immunohistochemistry (IHC) and the degree of inherent immunogenicity to NY-ESO-1. EXP...
The highly immunogenic human tumor antigen NY-ESO-1 (ESO) is a target of choice for anti-cancer immune therapy. In this study, we assessed spontaneous antibody (Ab) responses to ESO in a large cohort of patients with primary breast cancer (BC) and addressed the correlation between the presence of anti-ESO Ab, the expression of ESO in the tumors and their characteristics. We found detectable Ab ...
The presence of a metaphase cytogenetic abnormality (CA) is the key negative predictor of outcome in patients with multiple myeloma (MM). Gene expression profiling (GEP) of such patients showed increased expression of NY-ESO-1 compared to patients with normal cytogenetics (60% versus 31%; P = .004). NY-ESO-1 was also highly expressed in relapsing MM especially patients with CA (100% versus 60.7...
NY-ESO-1, a member of the cancer-testis family of antigens, is expressed in a subset of a broad range of different human tumor types. Patients with advanced NY-ESO-1-expressing tumors frequently develop humoral immunity to NY-ESO-1, and three HLA A2-restricted peptides were defined previously as targets for cytotoxic CD8(+) T cells in a melanoma patient with NY-ESO-1 antibody. The objectives of...
Evidence is growing for both humoral and cellular immune recognition of human tumor antigens. Antibodies with specificity for antigens initially recognized by cytotoxic T lymphocytes (CTLs), e.g., MAGE and tyrosinase, have been detected in melanoma patient sera, and CTLs with specificity for NY-ESO-1, a cancer-testis (CT) antigen initially identified by autologous antibody, have recently been i...
PURPOSE NY-ESO-1 (ESO), a tumor-specific antigen of the cancer/testis group, is presently viewed as an important model antigen for the development of generic anticancer vaccines. The ESO(119-143) region is immunodominant following immunization with a recombinant ESO vaccine. In this study, we generated DRB1*0101/ESO(119-143) tetramers and used them to assess CD4 T-cell responses in vaccinated p...
PURPOSE NY-ESO-1 belongs to a class of cancer/testis antigens and has been shown to be immunogenic in cancer patients. We synthesized a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein (CHP/ESO) and investigated the in vitro stimulation of CD8 and CD4 T cells from peripheral blood mononuclear cells in healthy donors with autologous CHP/ESO-loaded dendritic cells as ant...
NY-ESO-1 mRNA expression in transitional cell carcinoma was investigated by reverse transcription-PCR and immunohistochemistry. NY-ESO-1 mRNA was detected in 20 of 62 (32%) tumor specimens. There was a correlation between NY-ESO-1 expression and tumor grade: 0 of 4 (0%) grade 1 (G1), 6 of 26 (23%) grade 2 (G2), and 14 of 32 (44%) grade 3 (G3) tumors were NY-ESO-1 mRNA positive. Immunohistochemi...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید